PD-L1 status and Immune checkpoint inhibitors in kidney cancer: ignorance, lack of knowledge or both

World J Urol. 2022 Mar;40(3):887-888. doi: 10.1007/s00345-021-03624-6. Epub 2021 Feb 13.

Authors

Hossein Tezval¹, Jan Hinrich Braesen², Markus A Kuczyk³

Affiliations

¹ Department of Urology and Urological Oncology, Hannover Medical School, 30625, Hannover, Germany. tezval.hossein@mh-hannover.de.
² Institute of Pathology, Hannover Medical School, 30625, Hannover, Germany.
³ Department of Urology and Urological Oncology, Hannover Medical School, 30625, Hannover, Germany.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

B7-H1 Antigen
Biomarkers, Tumor
Humans
Immune Checkpoint Inhibitors* / therapeutic use
Kidney Neoplasms* / drug therapy

Substances

B7-H1 Antigen
Biomarkers, Tumor
Immune Checkpoint Inhibitors